ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost

Acrivon Therapeutics (NASDAQ:ACRV) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company announced a $130 million private placement.This new funding comes from a private investment in public equity (PIPE) with existing and new accredited investors. This has the company selling 8,235,000 shares of ACRV stock for$8.50 per share.The offer also includes pre-funded warrants for 7,060,000 shares being sold for $8.49 each. The exercise price for these warrants is one penny. They ...